Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Novartis, Pfizer and Gilead roll out COVID-19 vaccination rules as Delta makes case for mandates
'Forced into a virtual world': Can the tech that kept pharma R&D going through the pandemic tackle trial diversity, too?
Tenet COO and President Sutaria to take over for Rittenmeyer as CEO in September
Merck, Novo, Sanofi and more pull off China growth thanks to price maneuvering. But anxiety grows over outlook for biologics
HIMSS21: Hospitals, payers and startups clamoring to be 'digital front door,' and it's overwhelming patients
FDA finds fault with Axsome's depression filing, sinking stock
HIMSS21 Roundup—Zoom launches mobile browser for telehealth visits; Samsung unveils tech for 'smart hospitals'
GreenLight valued at $1.2B after riding from farm to Wall Street via SPAC
Senate passes infrastructure bill that restarts sequester cuts, delays rebate rule
COVID-19 tracker: Moderna tops Pfizer against Delta in new studies; U.S. to ship 8.5M doses to Mexico

Featured Story

Novartis, Pfizer and Gilead roll out COVID-19 vaccination rules as Delta makes case for mandates

By Fraiser Kansteiner

Over the past few days, Fierce Pharma asked a range of biopharmas big and small about their evolving vaccination policies. While some companies have already gone public with their plans, others are deliberating how to approach the issue.

'Forced into a virtual world': Can the tech that kept pharma R&D going through the pandemic tackle trial diversity, too?

By Annalee Armstrong

The pharmaceutical industry already knew virtual tools like decentralized studies, telehealth and home health visits could help make clinical trials more diverse. It just took a global pandemic to go all in on fixing the problem.

Tenet COO and President Sutaria to take over for Rittenmeyer as CEO in September

By Robert King

Tenet Healthcare's president and COO Saum Sutaria will become the hospital chain's new CEO starting in September, taking over for Ron Rittenmeyer who has led the system since 2017.

Merck, Novo, Sanofi and more pull off China growth thanks to price maneuvering. But anxiety grows over outlook for biologics

By Angus Liu

As innovative products ginned up sales growth for Big Pharma in China, companies have also found themselves playing defense for their mature brands against cheap generics. Meanwhile, a continually expanding price-cutting program now looks ready to tap into biologics, starting with insulins.

HIMSS21: Hospitals, payers and startups clamoring to be 'digital front door,' and it's overwhelming patients

By Dave Muoio

With more and more tools being targeted toward healthcare consumers, HIMSS21 panelists say stakeholders need to address the digital "Wild West" for the sake of the patient experience.

FDA finds fault with Axsome's depression filing, sinking stock

By Nick Paul Taylor

The FDA has identified deficiencies in Axsome Therapeutics’ submission for approval of AXS-05 in major depressive disorder. With less than two weeks to go until the PDUFA action date, Axsome is yet to learn the nature of the deficiencies or their implications for its filing.

HIMSS21 Roundup—Zoom launches mobile browser for telehealth visits; Samsung unveils tech for 'smart hospitals'

By Heather Landi,Dave Muoio

Here are a few slices of news and life from the first day of the 2021 Healthcare Information and Management Systems Society (HIMSS) Global Health Conference and Exhibition on Monday.

GreenLight valued at $1.2B after riding from farm to Wall Street via SPAC

By Kyle LaHucik

GreenLight Biosciences began its days in agriculture—think cows—and has since moved to human health to focus on, you guessed it, vaccines. Now, the ag and vax upstart is riding its way from the farm to the streets of New York City via a merger with special purpose acquisition company

Senate passes infrastructure bill that restarts sequester cuts, delays rebate rule

By Robert King

Providers should brace for the return of Medicare sequester payment cuts next year after the Senate passed a roughly $1 trillion bipartisan infrastructure package that includes the cuts as a pay for.

COVID-19 tracker: Moderna tops Pfizer against Delta in new studies; U.S. to ship 8.5M doses to Mexico

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Recent studies suggest that Moderna’s vaccine may be better at tackling the Delta variant when compared with the jab from Pfizer and BioNTech. The U.S. has agreed to send Mexico 8.5 million more doses as the two countries meet to discuss reopening their shared border. Plus more headlines.

PM Tracker